GoAI
Get started
INmune Bio, Inc. logo

INmune Bio, Inc.

INMB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.32

+$0.16 · +7.41%

Aug 21, 4:00 PM ET

INMB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

46

Fair Value

Momentum

79

Gaining

Sentiment

45

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David J. Moss
Listed since
Feb 4, 2019
Employees
21

Market position

Day range

Current $2.32

52-week range

Current $2.32

Open
$2.22
Previous close
$2.16
Volume
520.14K
0.83× average
Average volume
629.23K
Average daily volume
Market cap
61.68M USD
Beta
0.9
Market reference 1
50-day average
$1.7844
+30.02% above average
200-day average
$1.5613
+48.59% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
17.76M USD
P/E (TTM)
-3.36×
P/B (TTM)
3.04×
P/S (TTM)
0×
EV / EBITDA
-0.39×
Earnings yield
-110.75%
Free cash flow yield
-56.96%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-195.26%
Return on assets
-141.98%
Return on invested capital
-125.70%

Financial health

Debt / equity
0.07×
Current ratio
3.55×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends30564%-91291%-213145%-334999%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -16106.63%Operating margin, FY2022: -6938.77%Operating margin, FY2023: -19187.74%Operating margin, FY2024: -304535.71%Operating margin, FY2025: -61738.00%Net margin, FY2021: -16762.43%Net margin, FY2022: -7299.20%Net margin, FY2023: -19360.00%Net margin, FY2024: -300585.71%Net margin, FY2025: -91866.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -16106.63%. Operating margin FY2022 -6938.77%. Operating margin FY2023 -19187.74%. Operating margin FY2024 -304535.71%. Operating margin FY2025 -61738.00%. Net margin FY2021 -16762.43%. Net margin FY2022 -7299.20%. Net margin FY2023 -19360.00%. Net margin FY2024 -300585.71%. Net margin FY2025 -91866.00%.

Income trends

Revenue

50K USD+257.14%

Operating income

−30.87M USD+27.60%

Net income

−45.93M USD-9.15%
Income trends across reported periods5M USD−13.52M USD−32.04M USD−50.56M USDRevenue, FY2021: 181K USDRevenue, FY2022: 374K USDRevenue, FY2023: 155K USDRevenue, FY2024: 14K USDRevenue, FY2025: 50K USDOperating income, FY2021: −29.15M USDOperating income, FY2022: −25.95M USDOperating income, FY2023: −29.74M USDOperating income, FY2024: −42.64M USDOperating income, FY2025: −30.87M USDNet income, FY2021: −30.34M USDNet income, FY2022: −27.3M USDNet income, FY2023: −30.01M USDNet income, FY2024: −42.08M USDNet income, FY2025: −45.93M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 181K USD. Revenue FY2022 374K USD. Revenue FY2023 155K USD. Revenue FY2024 14K USD. Revenue FY2025 50K USD. Operating income FY2021 −29.15M USD. Operating income FY2022 −25.95M USD. Operating income FY2023 −29.74M USD. Operating income FY2024 −42.64M USD. Operating income FY2025 −30.87M USD. Net income FY2021 −30.34M USD. Net income FY2022 −27.3M USD. Net income FY2023 −30.01M USD. Net income FY2024 −42.08M USD. Net income FY2025 −45.93M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue50K USD14K USD155K USD374K USD181K USD
Gross profit50K USD14K USD155K USD374K USD181K USD
Research and development20.66M USD33.17M USD20.27M USD17.07M USD20.54M USD
Selling, general, and administrative10.26M USD9.48M USD9.62M USD9.26M USD8.79M USD
Operating expenses30.92M USD42.65M USD29.9M USD26.33M USD29.33M USD
Interest income850K USD————
Depreciation and amortization84K USD553K USD29.74M USD25.95M USD29.15M USD
Operating income−30.87M USD−42.64M USD−29.74M USD−25.95M USD−29.15M USD
Net income−45.93M USD−42.08M USD−30.01M USD−27.3M USD−30.34M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.86
FY2025
Latest fiscal-year revenue
50K USD
FY2025 · +257.14% year over year
Next fiscal-year EPS consensus
-0.55
FY2026 · 2 analysts
Next fiscal-year revenue consensus
133.33K USD
FY2026 · 4 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.06-0.81-1.55-2.3FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend35.11M22.35M9.59M-3.18MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$22.00

848.28% upside
Past 12 months12-month forecastHigh $22.00Average $22.00Low $22.00

Rating distribution

9 ratings
Strong buy00%
Buy667%
Hold222%
Sell111%
Strong sell00%

Recent analyst actions

4 institutions
LUCID CAPITAL MARKETSupgradeNeutralBuy
BTIGdowngradeBuyNeutral

INMB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding INMB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
857.97K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
342.99K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
178.55K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
11.21K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research INMB

research.disclaimer